| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Depression | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Depressive Disorder | |||||
| Depressive Disorder, Major | |||||
| 3 | More general conditions related to this trial | ||||
| Behavioral Symptoms | |||||
| Mental Disorders | |||||
| Mood Disorders | |||||
| 4 | Interventions listed in this trial | ||||
| Duloxetine Hydrochloride | |||||
| Venlafaxine Extended Release | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Duloxetine | |||||
| Venlafaxine | |||||
| 6 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic Uptake Inhibitors | |||||
| Antidepressive Agents | |||||
| Antidepressive Agents, Second-Generation | |||||
| Central Nervous System Agents | |||||
| Dopamine Agents | |||||
| Dopamine Uptake Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Neurotransmitter Uptake Inhibitors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Psychotropic Drugs | |||||
| Serotonin Agents | |||||
| Serotonin Uptake Inhibitors | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Eli Lilly and Company | |||||
|
